Showing results (281-290 of 716) with videos related to

Sort By:
Pageof 72
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phaseFabio P S Santos, Hagop Kantarjian, David McConkey, et al.
Molecular Cancer Therapeutics|September 3, 2009
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cellsDuncan H Mak, Wendy D Schober, Wenjing Chen, et al.
Leukemia & Lymphoma|July 16, 2005
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapyHagop M Kantarjian, Carlos E Bueso-Ramos, Moshe Talpaz, et al.
Cancer|June 22, 2010
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315INikolai Velev, Jorge Cortes, Richard Champlin, et al.
Cancer|June 12, 2009
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failureAlfonso Quintás-Cardama, Fabio Pires De Souza Santos, Hagop Kantarjian, et al.
The Lancet. Haematology|March 6, 2026
Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trialEsther N Olíva, Francesco Cottone, Sudhir Unni, et al.
Critical Reviews in Oncology/Hematology|January 23, 2017
Frontline treatment of acute myeloid leukemia in adultsGevorg Tamamyan, Tapan Kadia, Farhad Ravandi, et al.
American Journal of Clinical Pathology|October 23, 2012
Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemiaYi Zhou, Jeffrey L Jorgensen, Sa A Wang, et al.
Cancer|June 12, 2009
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phaseYesid Alvarado, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|December 13, 2005
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyGautam Borthakur, Hagop Kantarjian, George Daley, et al.
Pageof 72